The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat multi-drug resistant Pseudomonas and other infections in people with cystic fibrosis.
Site Search
Preston W. Campbell, III, President and CEO to retire; Michael P. Boyle, MD, appointed as successor effective January 2020.
The Department of Justice's decision to no longer defend critical provisions of the Affordable Care Act (ACA) risks health insurance coverage for people with cystic fibrosis and other pre-existing conditions.
The Cystic Fibrosis Foundation joins 15 patient and provider groups to oppose this bill, which would negatively impact patients' access to adequate and affordable health coverage and care.
A nonpartisan group of 29 patient, provider, and consumer groups praised the Senate Health, Education, Labor, and Pensions (HELP) Committee for crafting bipartisan legislation that will help stabilize the individual insurance markets.
The Cystic Fibrosis Foundation has announced the recipients of its first annual Impact Grants.
Ten patient and provider groups, representing millions of Americans, issued the following statement in response to the release of the nonpartisan Congressional Budget Office's (CBO) scores of two pieces of health care reform legislation currently being considered by the U.S. Senate.
Bipartisan legislation could help patients access necessary prescription drugs by potentially reducing the financial burden that results from complex and hard-to-navigate health insurance plans
Funding will support preclinical research and early-stage clinical trials
Cost effectiveness analysis must be used carefully and as part of a comprehensive evaluation of the value a treatment, such as highly effective modulators, provide to people living with cystic fibrosis.